Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Clinical and Experimental Gastroenterology|October 17, 2018
D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosisMichele Malaguarnera, Saverio Latteri, Gaetano Bertino, et al.
Health Psychology Research|February 8, 2021
Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2)Gaetano Bertino, Rosalia Ragusa, Liberato Simone Corsaro, et al.
World Journal of Gastroenterology|November 24, 2011
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirinMichele Malaguarnera, Marco Vacante, Maria Giordano, et al.
JMIR Research Protocols|May 27, 2021
Respiratory and Cardiovascular Health Effects of e-Cigarette Substitution: Protocol for Two Living Systematic ReviewsRenee O'Leary, Maria Ahmed Qureshi, Giusy Rita Maria La Rosa, et al.
Acta Histochemica|July 17, 2009
Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infectionFabio D'Amico, Maria Consolo, Alfredo Amoroso, et al.
Hepatitis Monthly|June 10, 2014
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical TrialGiulia Malaguarnera, Manuela Pennisi, Caterina Gagliano, et al.
Future Oncology (London, England)|October 11, 2013
Systemic therapies in hepatocellular carcinoma: present and futureGaetano Bertino, Isidoro Di Carlo, Annalisa Ardiri, et al.
American Journal of Translational Research|January 26, 2016
Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirinMichele Malaguarnera, Massimo Motta, Marco Vacante, et al.
Biomed Research International|November 28, 2013
Carbohydrate 19.9 antigen serum levels in liver diseaseGaetano Bertino, Annalisa Maria Ardiri, Giuseppe Stefano Calvagno, et al.
Hepatitis Monthly|November 17, 2011
Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patientsMichele Malaguarnera, Marco Vacante, Cristina Russo, et al.
Pageof 8